**Question:** 5-Lipo - oxygenase synthesis inhibitor is

A. Indomethacin
B. Naproxen
C. Celecoxib
D. Piroxicam

**Core Concept:**
The question is asking about a group of drugs called Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). NSAIDs inhibit the synthesis of prostaglandins, which are lipid compounds involved in various physiological processes, including pain, inflammation, and fever regulation. There are two main pathways for prostaglandin synthesis: cyclooxygenase (COX) pathway and lipoxygenase (LOX) pathway. The correct answer refers to a drug that specifically inhibits the LOX pathway.

**Why the Correct Answer is Right:**
The correct answer (D) Piroxicam is a NSAID that primarily inhibits the 5-lipoxygenase (5-LOX) enzyme, which is involved in the synthesis of leukotrienes and prostaglandins in the LOX pathway. This inhibition leads to reduced inflammation, pain, and fever. In comparison, indomethacin (A), naproxen (B), and celecoxib (C) primarily inhibit the cyclooxygenase (COX) pathway, which results in different side effects and clinical profiles.

**Why Each Wrong Option is Incorrect:**

A. Indomethacin is a COX inhibitor, specifically targeting both COX-1 (presynaptic) and COX-2 (postsynaptic) enzymes, leading to gastrointestinal and cardiovascular side effects.
B. Naproxen is a COX inhibitor as well, causing similar side effects to indomethacin.
C. Celecoxib is a COX-2 selective inhibitor, which reduces gastrointestinal side effects compared to traditional NSAIDs but increases cardiovascular risk.

**Clinical Pearl:**
The 5-lipoxygenase pathway inhibition by Piroxicam offers better gastrointestinal safety compared to non-selective and COX-2 selective inhibitors. While it is less selective, the primary inhibition of 5-LOX reduces the risk of gastrointestinal side effects compared to COX inhibitors. However, Piroxicam is contraindicated in patients with severe renal impairment, and it should be administered with caution in patients with cardiovascular risk factors.

**Correct Answer Explanation:**
The correct answer, Piroxicam, is a COX-1 and COX-2 inhibitor, primarily targeting the 5-Lipoxygenase (5-LOX) pathway. By inhibiting 5-LOX, Piroxicam reduces the production of leukotrienes, which cause inflammation, bronchoconstriction, and bronchospasm, contributing to asthma exacerbation.

Piroxicam is a COX-1 and COX-2 inhibitor, reducing gastrointestinal side effects associated with non-selective NSAIDs. However, it should be used with caution in patients with cardiovascular risk factors, as it may increase the risk of cardiovascular events due to inhibition of COX-2.

**Why It Matters:**
Understanding the mechanism of action and contraindications of Piroxic